716 related articles for article (PubMed ID: 30688081)
21. Baricitinib for the Treatment of Alopecia Areata.
Freitas E; Guttman-Yassky E; Torres T
Drugs; 2023 Jun; 83(9):761-770. PubMed ID: 37195491
[TBL] [Abstract][Full Text] [Related]
22. Which is the Ideal JAK Inhibitor for Alopecia Areata - Baricitinib, Tofacitinib, Ritlecitinib or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway.
Sardana K; Bathula S; Khurana A
Indian Dermatol Online J; 2023; 14(4):465-474. PubMed ID: 37521227
[TBL] [Abstract][Full Text] [Related]
23. The Effect of JAK Inhibitor on the Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells.
Kim JE; Lee YJ; Park HR; Lee DG; Jeong KH; Kang H
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32698510
[TBL] [Abstract][Full Text] [Related]
24. Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata.
Dai Z; Chen J; Chang Y; Christiano AM
JCI Insight; 2021 Apr; 6(7):. PubMed ID: 33830087
[TBL] [Abstract][Full Text] [Related]
25. Janus Kinase Inhibitors in the Treatment of Alopecia Areata.
Stefanis AJ
Prague Med Rep; 2023; 124(1):5-15. PubMed ID: 36763827
[TBL] [Abstract][Full Text] [Related]
26. Alopecia areata: What's new in the diagnosis and treatment with JAK inhibitors?
Dainichi T; Iwata M; Kaku Y
J Dermatol; 2024 Feb; 51(2):196-209. PubMed ID: 38087654
[TBL] [Abstract][Full Text] [Related]
27. The Evolving Story of JAK Inhibitors for Treating Alopecia Areata: A Review of Current Progress and Future Directions.
Donovan J
Skin Therapy Lett; 2023 May; 28(3):1-7. PubMed ID: 37339501
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2).
Kwon O; Senna MM; Sinclair R; Ito T; Dutronc Y; Lin CY; Yu G; Chiasserini C; McCollam J; Wu WS; King B
Am J Clin Dermatol; 2023 May; 24(3):443-451. PubMed ID: 36855020
[TBL] [Abstract][Full Text] [Related]
29. Alopecia Universalis Treated With Tofacitinib: The Role of JAK/STAT Inhibitors in Hair Regrowth.
Schwartzberg L; Spizuoco A
Cutis; 2023 Nov; 112(5):E5-E9. PubMed ID: 38091428
[TBL] [Abstract][Full Text] [Related]
30. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata.
Mackay-Wiggan J; Jabbari A; Nguyen N; Cerise JE; Clark C; Ulerio G; Furniss M; Vaughan R; Christiano AM; Clynes R
JCI Insight; 2016 Sep; 1(15):e89790. PubMed ID: 27699253
[No Abstract] [Full Text] [Related]
31. A Case of Topical Ruxolitinib Treatment Failure in Alopecia Areata.
Deeb M; Beach RA
J Cutan Med Surg; 2017; 21(6):562-563. PubMed ID: 28635319
[TBL] [Abstract][Full Text] [Related]
32. Recalcitrant alopecia areata responsive to leflunomide and anthralin-Potentially undiscovered JAK/STAT inhibitors?
Sardana K; Gupta A; Gautam RK
Pediatr Dermatol; 2018 Nov; 35(6):856-858. PubMed ID: 30318623
[TBL] [Abstract][Full Text] [Related]
33. Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib.
Fetter T; Rios GC; Niebel D; Bieber T; Wenzel J
Acta Derm Venereol; 2020 May; 100(10):adv00144. PubMed ID: 32285135
[TBL] [Abstract][Full Text] [Related]
34. Novel investigational drugs for alopecia areata and future perspectives.
Chim I; Ghiya R; Sinclair RD; Eisman S
Expert Opin Investig Drugs; 2024 May; 33(5):441-449. PubMed ID: 38682280
[TBL] [Abstract][Full Text] [Related]
35. [Janus kinase inhibitors for the treatment of alopecia areata].
Kobal I; Ramot Y
Hautarzt; 2022 May; 73(5):336-343. PubMed ID: 35482047
[TBL] [Abstract][Full Text] [Related]
36. Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents.
Liu LY; King BA
J Investig Dermatol Symp Proc; 2018 Jan; 19(1):S18-S20. PubMed ID: 29273099
[TBL] [Abstract][Full Text] [Related]
37. Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review.
Egeberg A; Linsell L; Johansson E; Durand F; Yu G; Vañó-Galván S
Dermatol Ther (Heidelb); 2023 Dec; 13(12):2951-2991. PubMed ID: 37833617
[TBL] [Abstract][Full Text] [Related]
38. Treatment of alopecia universalis with topical Janus kinase inhibitors - a double blind, placebo, and active controlled pilot study.
Bokhari L; Sinclair R
Int J Dermatol; 2018 Dec; 57(12):1464-1470. PubMed ID: 30160787
[TBL] [Abstract][Full Text] [Related]
39. Case Report: Successful Treatment of Alopecia Universalis With Tofacitinib and Increased Cytokine Levels: Normal Therapeutic Reaction or Danger Signal?
Yu L; Yu H; Zhang S; Hao Y; Zhang S
Front Immunol; 2022; 13():904156. PubMed ID: 35795663
[TBL] [Abstract][Full Text] [Related]
40. Ruxolitinib 1.5% Topical Cream for the Treatment of Pediatric Alopecia Areata.
Tembunde Y; Kindred C
J Drugs Dermatol; 2024 May; 23(5):378-379. PubMed ID: 38709705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
